The immune system and responses to cancer: coordinated evolution by Coventry, Brendon J et al.








The immune system and responses to cancer: coordinated evolution
Coventry, Brendon J ; Ashdown, Martin ; Henneberg, Maciej
Abstract: <ns4:p>This review explores the incessant evolutionary interaction and co-development be-
tween immune system evolution and somatic evolution, to put it into context with the short, over 60-year,
detailed human study of this extraordinary protective system. Over millions of years, the evolutionary
development of the immune system in most species has been continuously shaped by environmental inter-
actions between microbes, and aberrant somatic cells, including malignant cells. Not only has evolution
occurred in somatic cells to adapt to environmental pressures for survival purposes, but the immune
system and its function has been successively shaped by those same evolving somatic cells and microor-
ganisms through continuous adaptive symbiotic processes of progressive simultaneous immunological and
somatic change to provide what we observe today. Indeed, the immune system as an environmental
influence has also shaped somatic and microbial evolution. Although the immune system is tuned to
primarily controlling microbiological challenges for combatting infection, it can also remove damaged
and aberrant cells, including cancer cells to induce long-term cures. Our knowledge of how this occurs is
just emerging. Here we consider the connections between immunity, infection and cancer, by searching
back in time hundreds of millions of years to when multi-cellular organisms first began. We are gradually
appreciating that the immune system has evolved into a truly brilliant and efficient protective mechanism,
the importance of which we are just beginning to now comprehend. Understanding these aspects will
likely lead to more effective cancer and other therapies.</ns4:p>
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Introduction and Overview
It often goes unappreciated that the adaptive immune system 
developed hundreds of millions of years ago, and has evolved 
into a truly efficient protective mechanism, the importance 
of which we are just beginning to now understand in science 
and medicine. Acute immune responses have developed and 
evolved alongside infection and genetic diversity, as part of the 
entire evolutionary process of matching organism against organ-
ism. There has been a continuous development of the immune 
system’s capacity to protect an organism against infections 
through rapid genetic somatic mutations that also led to a 
dynamic, intricate interplay between genetic endowment and 
somatic mutations. The immune system acts as an ultimate high 
fidelity ‘read-out’ for cellular genetic change, detecting cellular 
aberration at the molecular level in its very early stages as it devel-
ops, to remove or destroy aberrant cells. Such aberration arises 
from infection of cells by viruses, bacteria or other microbes, 
and from DNA damage, failed repair mechanisms, mutagens, 
carcinogens including UV light, toxins and other chemicals, and 
from cellular damage and ageing, thus embracing a wide vari-
ety of mechanisms causing cellular aberration. Aberration is 
detected by a variety of innate non-specific immune mecha-
nisms through damage (or danger)-associated molecular pat-
terns (DAMPs) that are released in response to trauma or injury 
to tissues, such as heat-shock proteins (HSPs) when cancer 
cells are injured; and also pathogen associated molecular pat-
terns (PAMPs) which are a variety of molecules associated with 
(extrinsic) pathogens usually recognized by the innate immune 
system through toll-like receptors (TLRs) which include bac-
terial lipopolysaccharides, glycoconjugates, viral proteins and 
endotoxins. This might explain why addition of bacterial or 
viral antigens to cancer microenvironments (naturally or thera-
peutically) is observed to trigger successful adaptive immunity 
by supplying a suitable ‘danger signal’ in some situations. It 
is unclear whether the immune response is against the pathogen 
signal primarily, with secondary tumour killing; or drives for-
ward augmenting a pre-existing immune response against the 
cancer antigens by releasing inhibition. The recent anti-PD-1 
data would suggest the latter1.
Many pathogens contain intrinsic danger signals, due to an 
evolutionary adaptation selected-for over millions of years, 
capable of inducing an immune response in animal and human 
immune systems. Constant dynamic interaction occurs between 
cells and the immune system to preserve homeostasis. Because 
the rate of mutation during cell division and tissue turno-
ver far exceeds the rate of malignant tumour diagnosis, the 
immune system must serve in detecting and eliminating aber-
rant and frankly malignant cells at a developmentally early stage. 
MacFarlane Burnet proposed active immune surveillance occurs 
to detect cancer cells and virally infected cells to remove them 
from the body2–7. However, the fact that cancer does occur in 
humans and animals indicates that the process of detection and 
removal of malignant cells is not completely efficient. The rea-
son for cancer persistence likely resides with observations that 
in the chronic state of antigen persistence the immune system 
continually appears to repeatedly ‘close itself down’ to avoid 
over-activation and to conserve energy. In the acute state, with 
exposure to each new pathogen the immune system responds 
rapidly over several days and then typically retains ‘memory’ 
of that encounter, enabling more rapid responses upon subse-
quent exposure. If the antigen can be acutely removed from 
the system, the immune system returns to its steady basal 
state via homeostatic mechanisms. However, if the anti-
gen persists and cannot be removed from the organism, the 
immune system responds again and again with further cycles 
of activity. Over-reactivity is limited by eliciting an inhibitory 
response after each activation response, in the form of negative 
feedback for biological homeostatic damping. This cyclic feed-
back phenomenon is seen right across many, if not all, biologi-
cal systems in nature. In the chronic state, the immune system 
repeatedly activates in response to persistent antigenic signals. 
When the antigenic signal cannot be removed with a second 
‘round’ of activation, another cycle of activation and then inhibi-
tion occurs. This repetitive cycle continues until the antigenic 
focus is eventually removed, or the organism dies. Although 
this is an efficient system in the acute setting, in the chronic 
setting where the problem persists indefinitely and does not 
appear to resolve, ‘chronic inflammation’ can arise which is often 
far less energy efficient. Vast amounts of energy can be con-
sumed in chronic severe inflammatory conditions1. In areas of 
the world where infection has been effectively reduced by sani-
tation and other public health measures, non-infectious chronic 
inflammatory diseases have emerged as the major causes of 
morbidity and mortality. Clinically, this manifests as a relaps-
ing and remitting process, often with malaise and weight 
loss characteristic of many chronic illnesses. The ‘immunological 
damping’, although on one hand offering some anti-inflam-
matory advantage, results in rather maladaptive processes 
which consume excessive amounts of energy, that may damage 
surrounding tissues and cells. The relapsing and remitting phe-
nomenon is widely observable in states including chronic infec-
tions, chronic inflammatory diseases (like rheumatoid arthritis, 
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thyroiditis and multiple sclerosis), and cancers. Over a number 
of generations, natural selection has led to efficiency improve-
ments of immune responses. For instance, some specific chronic 
infections through co-adaptation of hosts and pathogens 
allowed normal (asymptomatic) functioning of most infected 
individuals; examples are endemic treponematoses8–10 or 
tuberculosis11,12.
This article considers the immune system more widely and 
relates cancer immunology in terms of the symbiotic evolu-
tionary relationships between the immune system, somatic cell 
evolution, microbial pressure and chronic inflammation.
Developmental Importance, Genome Diversity and 
Evolutionary Change
The immune system functions diversely across many organs 
to protect and maintain health. Importantly, the host’s immune 
system can regulate the genomic integrity across species and 
generations. Protection extends to all body barrier interfaces 
between the external and internal environment, where inva-
sion of microbial agents is prevented or dealt with. The protec-
tion also acts against deleterious somatic mutations of host cells. 
The immune system is vital for maintenance of the health of all 
other body systems.
Essentially, the process of DNA-based evolution, besides 
adapting organisms to their physical environments, has pit-
ted organism against organism in the quest for ultimate survival. 
According to Darwinian principles, the surviving organisms 
are the most successful in their reproduction either by con-
quering and terminating competing organisms, or in reaching 
symbiotic balance with them. That process requires protection 
of host DNA and also facilitates relatively rapid genomic con-
stitutional adaptation by acquiring and modifying useful DNA 
from the environment13. Indeed, the organism’s DNA is added 
to, modified and diversified to keep ahead of the ‘genetic supe-
rior adaptability game’ by mutation, plasmid transfer, viral trans-
duction, mitotic translocations, and meiotic acquisition to allow 
its successful reproduction. The immune system undergoes 
constant modification of innate and adaptive immunity with 
exposure to antigenic stimuli both at the individual and the 
population levels.
The mammalian immune system represents one of the final 
(to date) central arbiters over the course of human Darwinian 
evolution. Many of the advances necessary for human adapta-
tion have been moderated, directed and shaped by the influence 
of the immune system. Most fundamentally, the defense 
against infection and therefore survival of individuals to per-
mit reproduction, is underpinned by immune system function. 
Less obvious, though equally fundamental, is the role of the 
immune system in maintenance of the organism’s homeostasis 
through removal of cells whose somatic mutations made them 
deleterious or disadvantageous. Natural selection applies not 
only to the successful reproduction of entire organisms, but 
also to the clonal reproduction of cell lineages, both cancer and 
immunological, within an organism14.
The genes coding for the hypervariable regions of the antibody 
molecule and the genes for the variable regions of the T-cell 
receptor, mutate at a much faster rate than somatic genes under 
usual environmental pressure. The critical process of V(D)J 
gene recombination during T and B lymphocyte development 
randomly assembles different gene segments – named vari-
able (V), diversity (D) and joining (J) genes, to generate immu-
noglobulin molecules and T cell receptors that can recognise 
antigens to which either the host or its genetic ancestors might 
have had exposure permitting binding and responsiveness to 
both new or changing antigens. These processes allow for more 
diverse binding patterns for antigens by both antibodies and 
T-cell receptors, which has significant immune adaptational 
advantage15,16. Somatic mutation on the other hand is a relatively 
slow process where genetic changes through (often) weaker 
selection pressures on survival and reproduction usually require 
some generations of cell divisions and progeny. These, changes, 
however, perceived as “millenial” can happen over just a few 
generations17–19. The immune system genes, however, con-
stantly rapidly mutate in order to generate diverse conformations 
capable of binding the multitude of antigens to which an indi-
vidual is exposed. Many of those antigens might be associated 
with threat and danger, for example, from microbial invasion. 
Examples of the somatic hypermutation process in B-cells are 
antibody class switching, and hypermutation of the genes for 
the variable regions of immunoglobulin molecules permit-
ting the rapid antibody recognition of new foreign antigens 
with different molecular shapes. The immune system design 
has necessarily evolved, through continuous successive approxi-
mation, to detect subtle molecular cell surface aberrations. This 
occurs through both non-specific, and specific B- and T-cell, 
mechanisms in an elegantly integrated manner.
How the Genome Monitors Itself and Evolves
Somatic changes of organisms generally occur at a gradual 
pace of varied rates as part of the slow, but effective, evolution-
ary process through such mechanisms as random mutation, 
natural selection and viral infection. For example, human mor-
phological characteristics, like stature, brain size and tooth size 
change at rates ranging from 0.3 darwins to 65 darwins17. Micro-
bial DNA sequences, for example from retroviruses like HIV, 
Herpes viruses and Mycobacterium tuberculosis, have been 
identified in the human genome, and these genes must have been 
structurally incorporated over time from repeated exposure, 
interaction and exchange between mammalian and microbial 
DNA20,21. Human Endogenous Retroviruses (HERVs) are esti-
mated to make up to 8% of the human genome, though fragmented 
and replication incompetent, it bears testament to long and inti-
mate genetic interactions between a parasite with a few genes 
and 10,000 nucleotides, and a host of some 22,000 genes and 
some 2.85 billion nucleotides22–24. Interestingly, the (unin-
fected) C57 black mouse has several whole genomic copies of 
the LMP56 retrovirus in its germline23. Clearly, the retrovirus 
became inserted into the murine genetic complement in the mam-
mal’s evolutionary past23–27. When infected with the virus in the 
experimental situation, the mouse develops a chronic immu-
nodeficiency disease, the clinical course of which parallels 
HIV/AIDS in humans28. It is now suggested that this chronic 
disease state is due to the murine immune system failing to 
differentiate between self and non-self, such that it homeo-
statically attenuates or down-regulates the immune response 
against the virus in vivo29,30. Failure to resolve the disease is due 
to persisting viral (self) antigens. The experimental similarity 
to the immune response in murine cancer models is strikingly 
compelling. In the case of cancer in the mouse the persisting 
antigens are due to the growing cancer which appears to exert 
a similar attenuating effect31.
Over the millennia the constant exchange of genetic material 
between host and environmental microorganisms has offered 
incremental adaptive advantage to both organisms (host-
pathogen adaptation), but in fundamentally different ways, 
perhaps comprising the ultimate symbiotic relationship, since 
both have evolved and survived32. There remains a debate over 
whether the presence of microbial DNA is the result of incor-
poration or failed gene loss of inherited genes as evolution has 
occurred33–36. However, many microorganisms can expand rapidly, 
possess mechanisms for evasion of host defences, and can 
mutate at a rate that far outpaces somatic evolutionary change 
via much faster division/reproduction rates. This may explain 
the immune system’s evolved ability to match these rapid 
microbial mutational rates to more effectively neutralize them 
via innate mechanisms, antibody production and cellular 
responses. Examples are the microorganisms that rapidly expand 
and produce outbreaks of disease in humans, animals (from 
insects to mammals), and, plants, sometimes with transmis-
sion across species. Rapid, immediate ‘revolutionary’ adaptive 
change is advantageous to keep the immune system ahead of 
microbial mutation, virulence and growth37. To oppose mutated, 
infected and otherwise aberrant cells, the immune system has 
a number of adaptive and protective mechanisms. These include 
somatic hypermutation genes for generation of hypervariable 
region binding domains for antibody molecules produced by 
plasma (B-) cells, and for the process of genetic recombination 
by T-cells forming the variable regions of T-cell surface recep-
tors for rapid response to antigen exposure. In this way, adaptive 
immune responses can rapidly generate multiple molecules 
with variable affinity for binding whole or fragmented antigens. 
An analogy would be ‘random number generation’ to break 
undeciphered digital codes, or in contemporary terms to ‘hack 
into’ a computer system across encrypted firewalls38–40 .
Without adequate host organism defence, infection would 
cause cellular damage and death. Humans are estimated to har-
bour some 1014 microbes, mostly bacteria, while we consist of 
only 1013 mammalian cells41–43. It might therefore be argued 
that in a cellular sense we are more bacterial than mamma-
lian in constitution. The human body, like any other multicel-
lular organism, should be treated as a complex ecosystem whose 
balance is dynamically maintained by feedback interactions 
amongst its parts.
To understand the human immune system, we must appreci-
ate that each facet of the immune system has evolved con-
currently as life itself has evolved. The mammalian genome, 
therefore constantly monitors itself through the actions of the 
immune system, both non-specific and adaptive. This is in order 
to achieve a state of evolving homeostasis to achieve progressive 
protection of the genome, and of cellular and tissue function, as 
the environmental, microbial and other pressures continually 
change.
History of Immune System Development and 
Cellular Aberration
Life on earth commenced between 3 and 4 Ga (giga or billion 
years ago; 3–4x109 years) as unicellular organisms (fungi, bac-
teria and viruses) adapted to survive environmental hazards 
through rapid reproduction, colony formation and repopula-
tion. At some 1.2 Ga algal mats developed as the first multicel-
lular organisms, and then about 1 Ga more complex chlorophyll-
containing organisms evolved. About 450 Ma (mega or million 
years ago) even more complex plants developed and acquired 
fundamental innate static immune systems largely through intra-
cellular anti-microbial molecules to resist infection principally 
from existing fungi, bacteria and viruses.
Recent studies indicate that sponges and other invertebrates 
developed both innate and adaptive immunity at around 800 
Ma ago so that from that period marine sponges, coelenterates, 
gastropods (snails & slugs) and helminths (worms) possessed 
the ability for allograft rejection, indicating distinction between 
self and non-self44,45. A further advance in adaptive immu-
nity developed with vertebrates around 450 Ma in primitive fish 
and amphibians, and with reptiles, about 300 Ma, this evolved 
rapidly for protection against infection.
Mammalian life began about 120 Ma, with immune sys-
tem evolution to meet the need for local and systemic protec-
tion from invasive microorganisms, and with placentation32. 
Indeed, for effective adaptive symbiosis the mammalian immune 
system must have developed evolutionary tolerance for spe-
cific microorganisms since some organisms conferred adaptive 
advantages and others did not. A part of these adaptations 
may have been inherited from therapsid ancestors.
In contrast to the 3–4 billion years of immune system evolution, 
for only a mere 60 years or so, humans have more intensively 
investigated the immune system and its intricate interplay 
between non-specific (innate) and more specific (adaptive) 
immune mechanisms for fundamental evolutionary and develop-
mental advantage. Often viewed as separate arms of the immune 
response, it is clear that they are rarely mutually exclusive 
or separate. The ‘artificial’ division arose for experimental 
explanatory research reasons, rather than physiological ones, but 
both are inextricably inseparable.
Genomic intrinsic mutational phenomena and exogenous 
infection of cells are significant forces capable of exerting phe-
notypic change to produce cell membrane ‘aberration’. Dur-
ing cellular transformation to dysplasia, metaplasia and malig-
nancy, cell membrane changes are detectable. Since gene 
mutations occur about 1 in every 106 cell divisions, the risk of 
cellular aberration is high in rapidly dividing tissues, with some 
leading to malignant transformation. The immune system is the 
only system capable of high-level detection and action, and must 
therefore detect aberrant cells early and remove them exceed-
ingly effectively and efficiently, otherwise, the rates of can-
cers would exceed that observed clinically. About 106 cells 
form a 5mm diameter tumour mass from some 30 divisions 
(assuming a regular process applies).
Progressive exposure to environmental antigens in-utero, dur-
ing infancy and subsequently, ultimately leads to acquisition 
of a very individual repertoire of antigens for which immuno-
logical tolerance and memory are established, thus shaping the 
immune system over time with the maturity of the individ-
ual enhancing adaptive immunity and survival. Recent data 
indicate that early antigenic exposure, including through the 
microbiome, transplacentally and during infancy is related to 
antigen tolerance and that lack of exposure is associated with 
higher allergic sensitisation and atopic reactions. There is also 
evidence that the level of antigen exposure (dose) is important in 
induction of T-cell responses and tolerant states to antigens46,47 
and that progressive sensitisation with small repetitive doses of 
antigen can induce (variable) tolerance to serious peanut and 
bee-sting allergy48,49–52, with some relevance to the breaking of 
immune tolerance to cancer1,53,54.
The link between the extent of environmental exposure to 
antigens shaping and developing the immune system and the 
incidence of disorders such as chronic infections, allergy and 
cancer has been extensively discussed49–54 and remain topics of 
considerable on-going interest.
Fundamental Reactivity to Aberrant Antigens
Aberrations, arising from multiple events such as infec-
tion of cells, cellular injury, trauma, ageing or from genetic 
mutation, are reflected by cell surface expression of aberrant 
proteins, lipids (especially glycolipids) and carbohydrates. 
Detection of aberration through both non-specific and spe-
cific adaptive mechanisms is essential for destruction and 
removal of abnormal cells to restore tissue integrity. Mem-
brane profile alterations from normal to dysplastic and malig-
nant transformation are evident using magnetic resonance 
spectroscopy55–57. The immune system is carefully tuned to 
detect relatively subtle changes in proteins through the stand-
ard HLA systems via Class I and II molecules, and the far less 
explored CD1 system for the detection of lipid, glycolipid and 
carbohydrate molecules58. In addition, the Fc receptor mecha-
nism of the non-specific arm of the immune system detects for-
eign and altered cells. Activation of granulocytes, macrophages, 
B-cells and T-cells pushes the immune system in one direction 
or in the other, producing either overall responsiveness/activa-
tion, or inhibition/tolerance. Increasingly, it is being appreciated 
that almost all levels of the immune system can either respond 
or inhibit, providing a certain redundancy at multiple levels 
of control. Therefore, infected, damaged or malignant cells can 
be either actively eliminated or tolerated. Clinically, this is pre-
cisely what is observed, in a variety of infections and malignan-
cies. Indeed, chronic inflammatory states have emerged as the 
predominant illnesses affecting many individuals, including per-
sistent infections, autoimmunity and malignancy. Diseases such 
as cancer, cardiovascular disease and diabetes are now appreci-
ated as chronic persistent inflammatory states, capable of modu-
lation by factors such as anti-inflammatory medication and 
immune modulation.
Evolutionary Roots of Cancer
In recent years there has been increasing interest in cancer as 
a biological phenomenon found across almost all multicellular 
species59 suggesting deep evolutionary roots dating back to the 
dawn of multicellularity. The transition from unicellularity to 
multicellularity occurred several times starting over one bil-
lion years ago, although evolutionarily modern multicellular 
organisms with a large variety of cell and tissue types did not 
emerge until the Ediacara and Cambrian eras <600 million 
years ago. In 1929, Boveri60 proposed that cancer represents a 
type of atavism or reversion to a more primitive ancestral phe-
notype. This general idea has now been widely confirmed using 
phylostratigraphy to study the evolutionary ages of cancer genes. 
It is generally recognized that the genes responsible for cel-
lular cooperation in multicellular organisms (e.g. signalling, 
adhesion, angiogenesis, migration) are precisely those genes 
that are corrupted in cancer and lead to loss of regulatory 
function61–63.
In a series of papers64–68, Boveri’s idea of cancer as a type of ata-
vism has been developed into a detailed theory of cancer onset 
and progression, which makes many quantitative predictions 
testable using phylostratigraphy.
It has long been recognized that there is a close link 
between cancer and early-stage embryogenesis69–71 which makes 
sense in the context of the atavism theory given von Baer’s 1828 
so-called 4th law of embryology: “The embryo of a higher ani-
mal form never resembles the adult of another animal form, such 
as one less evolved, but only its embryo.” Although ‘law’ is an 
overstatement, Haekel’s much-criticised 1866 aphorism ‘ontog-
eny recapitulates phylogeny’ is nevertheless still a useful 
guide72, and supported by evidence that complex interactions 
between genes, cells and developmental processes peak during 
mid-embryogenesis when the basic body plan of the organ-
ism is being laid down73. The atavism theory predicts that as 
cancer progresses, cells de-differentiate towards ‘stemness’ 
and in a general sense resemble more closely the cells of both 
early stage embryogenesis and the unicellular world.
Phylostratigraphic analyses relevant to cancer began with 
the pioneering work of Domazet-Lošo & Tautz74. They 
assigned ages to ‘cancer-associated genes’ from several cancer 
gene compilations and found two peaks where cancer genes 
are over-represented compared to the age distribution of all 
human genes. One was in the pre-eukaryote unicellular era. The 
other correlated with the origin of multicellularity and meta-
zoa. The most important finding was the under-representation 
of cancer-associated genes younger than about 400 million 
years, confirming the basic notion that the evolutionary roots 
of cancer are very ancient.
Chen et al. set out to test the atavism model by examining 
xenograft human breast tumours in mice and characterized the 
complete evolutionary history of a tumour75. The expression pro-
files were found to evolve towards that of embryonic stem cells. 
The most highly mutated and consistently downregulated 
genes in the metastatic samples were enriched in functions 
related to multicellularity. In another analysis, the phylogenetic 
tree of Tyrosine Kinases (TKs), which compose a major por-
tion of oncogenes, demonstrated “a general trend of atavism in 
tumourigenesis”76. Studies by Wu et al. of multiple myeloma 
evolving in a microfabricated ecosystem also supported the gen-
eral thesis that “cancer represents a reversion back to ancient 
forms of life”77.
An Australian group applied phylostratigraphy to RNA tran-
script sequencing data from The Cancer Genome Atlas for 
seven solid cancers, using 16 age categories78. Consistent with 
Domazet-Lošo & Tautz74, they found significant patterns in the 
relationship between gene age and expression levels in can-
cer. Genes of unicellular evolutionary origin are over-expressed 
in human cancers, whereas genes appearing at multicellular 
stages are down-regulated. The over-expression of unicellu-
lar genes was associated with major dysregulation of the con-
trol structures imposed on unicellular processes during the 
evolution of multicellularity. Significantly, Trigos et al. found 
that the atavistic signature was not a simple re-primitivisation 
to unicellularity. Rather it is a rewiring of the coupling between 
the gene networks that control unicellular processes from 
those that control multicellular processes79. Their results thus 
provide evidence that cancer is a nuanced reorganization of 
the relationship between the unicellular and multicellular 
domains. A key prediction of this theory is that the reversion-
ary sequence is systematic and should display regularities across 
species and across cancer types.
Zhou et al.80 examined transcriptomes to compare differen-
tial gene expression between normal and cancer cells, and 
between embryonic and mature epithelial cells. Starting with 
11 phylostrata, they made 5 age bins: LUCA, Eukaryota, Meta-
zoa, Vertebrata, Primata, and then reduced these to two bins: 
pre-metazoan and post-metazoan. They found that compared 
to normal cells, cancer cells were enhanced in pre-metazoan 
and depleted in post-metazoan gene expression. Compared to 
embryonic cells, differentiated epithelial cells were enriched 
in post-metazoan expression. Their summary: “These find-
ings support the atavism theory that cancer cells manifest the 
reactivation of an ancient ancestral state featuring unicellular 
modalities.”
Using phylostratigraphy, Cisneros et al.81 found that reces-
sive cancer genes older than 900 million years are homologs 
of the ancient genes in bacteria that turn up mutation rates 
when the cells are stressed–suggesting that the well-known 
genomic instability of cancer can be interpreted as a rever-
sion to an ancient prokaryotic stress response, a phenomenon 
recently confirmed by the analysis of Cipponi et al.82 showing 
mTOR (mammalian target of rapamycin) signaling orchestrates 
stress-induced mutagenesis, facilitating adaptive evolution in 
cancer.
The retention over evolutionary time scales of a DNA repair 
mechanism that increases the mutation rate in response to 
cellular stress may seem counter-intuitive. One reason is 
that the generation of somatic genome diversity is critical to the 
functioning of the immune system via somatic hypermutation 
of V regions to generate antibody diversity83. Somatic genome 
diversity is also implicated in the implementation of poly-
ploidy in megakaryocyte development84, and the appearance of 
tetraploidy in normally functioning liver and cardiac tissues85.
Cancer is conveniently characterized as displaying a set of 
distinctive hallmarks86 which represent both gain and loss of 
function. Significantly, cancer does not evolve the hallmark 
properties ab initio; neoplasms merely appropriate pre-existing 
modalities latent in the genome75,87, retained because they 
play critical roles in key processes such as genetic diversity, 
embryogenesis, tissue maintenance and wound healing71,88.
A central prediction of the atavism theory is that there should 
be definite patterns in the direction, order and timing of both 
the loss and gain of function as cancer progresses, occurring 
via a sequence of increasingly malignant transformations89. Can-
cer progression should roughly correlate inversely with the 
chronological sequence in which the relevant cancer genes 
evolved phylogenetically. By contrast, Hanahan & Weinberg 
(2015) remark: “The order in which these hallmark capabilities 
are acquired…appears to vary across the spectrum of human 
cancers.” Thus, the existence of non-randomness in hallmark 
acquisition provides a useful test to discriminate between the 
atavism theory and the prevailing somatic mutation theory. 
Evidence for the non-random nature of hallmark acquisition 
has been identified by Lineweaver and Chopra90.
A well-known hallmark of cancer is its ability to evade or block 
the adaptive immune system, a feature that forms the basis 
of immunotherapy. Given the relatively young evolutionary 
age of adaptive immunity (< 500 million years), the atavism 
theory predicts that adaptive immunity should be lost soon after 
the onset of tumourigenesis65. Another familiar hallmark is the 
default in cancer metabolism to anaerobic glycolysis even in 
the presence of normal oxygen tension, a phenomenon known 
as the Warburg effect91. Glycolytic metabolism is well adapted 
to hypoxic environments of the sort encountered in tumours, 
but was also the normal circumstance for life before the great 
oxygenation event about 800 million years ago. By upregulating 
the Warburg effect, cancer can be regarded as reverting to 
the ancient hypoxic roots of early multicellular life. Indeed, 
it has been argued by Vincent65 that cancer engineers its tis-
sue microenvironment to recreate congenial atavistic niches in 
which neoplasms can flourish in competition with healthy cells.
The atavism theory has important implications for therapy65. 
The history of the interaction of bacteria, viruses and cancer is 
a very long and somewhat confused one, since William Coley 
obtained some notable clinical results over a century ago92. 
Some infections will boost the immune system and bring addi-
tional pressure on cancer cells, but some agents will directly 
infect the cancer cells preferentially in their immunosup-
pressed niches, for example oncolytic viruses. A variety of 
new approaches1,93–99 to immunotherapy exploits these features. 
The atavism theory predicts that advanced cancer will be par-
ticularly vulnerable to certain infectious agents, and specific 
treatment regimes have been advocated to take advantage of 
that aspect65.
We also note that, taking into account the discovery of stress-
induced mutagenesis – a very ancient stress response found 
in bacteria and pre-dating multicellularity – the practice of 
maximum tolerable dose for chemotherapy is likely to be coun-
terproductive. It risks provoking an elevation of the mutation 
rate (another hallmark of cancer), thus facilitating the abil-
ity of the neoplasm to evolve drug resistance. Instead, a more 
measured and nuanced treatment regime is likely to be more 
efficacious.
Contemporary Cancer Evolution
Not only is there an evolutionary past of considerable longev-
ity, but the tumour deposit itself has frequently been demon-
strated to have wide genetic heterogeneity arising from the 
initially clonal multi-cellular growth, and moreover different 
metastases show considerable heterogeneity between them. It 
is therefore evident that the ‘cancer’ is not truly clonal, but rep-
resents a mix of cells resulting from genetic instability with 
different genetic profiles, which the immune system must 
recognise in order to react to remove the constituent cancer 
cells within the tumour mass(es)100–104. Cancer phenotype has 
been proposed as an evolutionary interaction between nor-
mal and malignant cells105, and furthermore, recent evidence 
indicates that the hierarchical structures in normal host tis-
sues are structurally mirrored in a very similar way by tumour 
tissues106. Additionally, mathematical models have been devel-
oped to investigate how de-differentiation of tumour cells 
appears to be an adaptive mechanism actively selected-for to 
permit invasion into cellular hierarchies106.
Homeostatic Regulation of Immune Reactivity and 
Cancer
The relapsing and remitting behaviour of many chronic inflam-
matory states, such as arthritis, inflammatory bowel diseases, 
multiple sclerosis, and thyroiditis is well recognised. Diabetes, 
cardiovascular diseases and cancers of all types are now being 
considered similarly. The fluctuating, oscillating nature of these 
diseases has largely confounded our understanding to date and 
remained frustratingly unexplained, but is indicative that the 
immune system must be repeatedly transitioning between stimu-
lation/activation and suppression/tolerance phases repeatedly 
to produce the observed clinical picture. Moreover, oscillatory 
behaviour is highly characteristic of any homeostatic biological 
system under negative feedback control. This cyclical dynamic 
is a physical expression of physiological control to maintain 
relative constancy of the milieu intérieur, as recognised by 
Claude Bernard around 1867, and later by Walter Cannon. 
Physiological constancy, or homeostatic control, of the body’s 
immune status requires proportioned synchrony between effec-
tor stimulation and regulatory functions to be operational. 
Many cyclical examples, such as the diurnal temperature cycles, 
peri-monthly menstrual cycles, and 24-hour cortisol cycles 
have been elucidated by close serial monitoring. The fluctuat-
ing pattern in these situations defines the “set-point” which that 
specific physiological parameter is maintained at to define the 
mean and standard deviation of that variable.
The association between cancer and the host immune response 
has been recognised for over a century107–112. In animals, 
North et al.’s group113–121 and more recently Klatzmann et al.’s 
group122, demonstrated that the timing of delivery of cytotoxic 
agents after tumour transplantation was crucial in determin-
ing whether tumour regression occurred or not. Early clinical 
observations of inflammation and cancer regression were made 
by those treating cancer107–110, particularly the development of 
infection/fever after surgery. Chronic inflammation has long 
been associated with cancer development, for example chronic 
ulceration and Marjolin’s squamous cell cancer of the skin.
The immune system has innate and adaptive arms. Chemicals 
are released into the serum during inflammatory responses 
and can be used as clinical and laboratory markers of the pres-
ence and strength of inflammation. These can be used to 
infer the rate of increase or decrease of inflammation that 
is occurring at the time and are dependent on the half-lives of 
the relevant marker(s), and often other factors such as organ 
function. Acute phase markers include C-Reactive Protein 
(CRP), serum amyloid A, complement factors, ferritin, ceru-
loplasmin, erythrocyte sedimentation rate, white blood cell 
count, haptoglobin, immunoglobulin and a range of cytokines 
released into the serum and/or tissue. Many of these tests are 
routinely used clinically for measurement of inflammation 
and for monitoring of treatment and disease progression.
One of the easiest to measure, is the relatively reliable and 
clinically widely useful acute phase marker CRP, a non-spe-
cific functional analogue of immunoglobulin that binds to 
self/non-self cellular breakdown products of inflammation 
to initiate the adaptive immune responses123,124. T & B cells 
respond to cellular changes due to infection, damage or muta-
genesis. To fine-tune and limit these responses, the ensuing 
immune response is down-regulated paradoxically by the same 
cytokines and receptors that initiated it, but on function-
ally different cell types. Regulatory T-cells play a major role 
in this homeostatic attenuation and experimental and clinical 
evidence has shown that when these cells are either removed 
or blocked, cancer can completely regress, while autoimmune 
conditions may develop or worsen125–130.
In recent years, it has become clear that the immune sys-
tem recognises and processes both self- and non-self antigens 
to either respond or tolerate the antigen, but that homeostatic 
balance usually prevails.
Immune responses can therefore be thought of as an oscillat-
ing or dual-phase “bi-stable” system existing in either of two 
principal states (responsiveness or tolerance). Antigen is the 
prime mover for either of these two states, and cytokines, most 
notably interleukin-2 (IL2) as an example (but also includ-
ing IL-7, IL-10; IL-12; IL-15; IL-17; IL-21; IFN-γ) and 
other molecules (eg. anti-PD-1, anti-CTLA4), provide the 
temporal feedback loop to govern the immune response direc-
tion. If antigen is continuously supplied to such a system (due 
to tumour cell growth/ turnover) logic and physiology dictate 
that this response must oscillate123,124,131–134. Oscillatory sys-
tems are characteristic of any homeostatic system with feedback 
loop(s) (Figure 1).
Not only is the immune response governed by ‘when’ the 
cytokine or antigen signals are delivered, but also by the 
strength (how much) of the signal that is delivered. Small 
quantities of cytokine, IL-2 for example, induces a different 
effect to a larger quantity of the same cytokine – a point exploited 
to some degree in IL-2 therapies135–138.
Anti-cancer Agents and Immune Responses
Cytotoxic agents inhibit cell division to therapeutically dam-
ageand kill tumour cells. However, cancer cells divide 
asynchronously. About 20–30% of malignant cells within many 
solid cancers are dividing at any one time-point (greater rates 
of division occur in some cancers such as childhood leukae-
mia, choriocarcinoma and testicular carcinoma). Regimens 
have evolved often with weekly dosing of sequential ‘lines’ 
(1st, 2nd, 3rd etc) of therapy or in combinations. Repeti-
tive dosing of agents inducing multiple cycles of cell dam-
age and antigen release (vaccination events) from the tumour is 
emerging as highly significant1,54,123,131.
Cells of the immune system rapidly divide, but they usually 
divide synchronously and the arms of the immune response 
proliferate alternately (effector then regulatory) at different 
times sequentially to initiate then reduce an immune response 
over time123,124,131–134.
Cytotoxic agents, as well as desirably ablating actively divid-
ing cancer cells, unless applied discriminately, are capable of 
ablating different groups of proliferating immunological cells, 
including proliferating effector T-cells.
Figure 1. C-Reactive Protein (CRP) Level Fluctuation. An example of CRP oscillatory behaviour in a patient with cancer - an example of 
the immune system fluctuating with a varying inflammatory response to an antigen stimulus. Several CRP levels (results) were taken each 
day. Antigen is capable of driving activation or inhibition depending on the strength and timing of the signal input and on operational 
feedback facilitatory and inhibitory loops, alternately driving both responsiveness and tolerance to create net homeostasis around a 
set-point mean. Multiple cytokines (eg. IL-2, IL-7, IL-10; IL-12; IL-17; IL-21; IFN-γ) and other molecules (eg. anti-PD-1, anti-CTLA4, antigen) 
have the capability of either activating or inhibiting immune responses, so are bi-functional.
It is now clear that the immune system is not ignorant to 
the presence of tumours, that it does recognise tumour anti-
gens, and that the normal homeostatic regulatory mechanisms 
suppress active anti-tumour immune responses, and are at the 
seat of the problem. This explains why immuno-modulatory 
agents, such as IL2, and CTLA4, PD1/L1 monoclonal antibod-
ies can deliver random dramatic complete responses in a lim-
ited percentage of late-stage cancer patients by releasing the 
pre-existing homeostatic suppression/tolerance1,125–130. All of 
these immunotherapeutic agents can induce immune activa-
tion, but can also induce immune tolerance. The lack of efficacy 
of these agents in most patients is explained by induction of tol-
erance with some doses via regulatory T-cells while activating 
with other doses, the net balance of which might determine 
overall clinical outcome.
The application of immune therapies or cytotoxic chemothera-
pies to the oscillating and fluctuating immune system occur-
ring in the individual patient presents a significant problem 
if the action of the specific agent depends on precisely when 
the agent is administered with reference to the phase of acti-
vation or inhibition of the immune system at the time. Recent 
work has been unable to accurately define the periodicity of 
the immune oscillation in cancer patients despite initial work 
using less robust mathematics appearing to show this139–142. 
Advanced mathematics and periodicity models have been inca-
pable of verifying regular, consistent, clear, regular immune 
cycles, principally due to infrequent inflammatory marker serial 
sampling and confounding noise-to-signal issues, but machine 
(deep) learning may offer alternative methods. On-going work 
into the oscillatory behaviour of the immune system, espe-
cially in advanced cancer patients, may reasonably offer useful 
opportunity to understand and to forecast or predict treatment 
intervention more accurately than exists at present143.
Improving results of natural selection
Tissues in the body are usually maintained with a very uni-
form cell composition. Most aberrant cells appearing in the 
human body as a result of somatic mutations are detected and 
disposed of by the immune system. Some are not and can pro-
duce pathology, with the majority of clinical cases of cancer 
occurring in older patients. This is explicable by the fact that 
natural selection operates principally by differential reproduction, 
consequently it is unable to operate for selection of biological 
characteristics in non-reproductive (older) individuals. Thus, over 
the generations immune responses to malignant cells appear-
ing in young people became adjusted by natural selection and, 
statistically speaking, operate efficiently, while such responses 
in older age were not “reachable” by natural selection for 
genetic adjustment. This principle is not only applicable to spe-
cific immune responses, but encompasses the entire regula-
tion of homeostatic balance of an organism. In practical terms, 
clinical intervention should imitate adaptation by selection of 
immunological processes occurring in younger organisms, to 
support, adjust and enhance natural operation of immune sys-
tems of older patients. Since the onset of significant clinical 
interventions about a century ago, death has been reduced such 
that the operational pressures of natural selection have been 
relaxed and, as one of the consequences, the incidence of many 
cancers has increased19, while concurrently improved treatments 
have also extended the lives of many patients.
Concluding Remarks and Implications
Although knowledge has deeply developed concerning the 
immune system and cancer immunology, our contemporary 
understanding needs to be placed in evolutionary perspective. 
Our immune systems are the adaptive result of the necessity for 
defence against persistent selective pressures from environmen-
tal microbial pathogens, injury and repair. Over the millennia, 
the immune system and other body cells have undergone 
a continuous adaptive symbiotic process of synchronous, coor-
dinated, cooperative, progressive immunological and somatic 
evolutionary change to provide what we observe today. Gradual 
evolution of innate and adaptive immunity against infected and 
aberrant cells now explains many of the observations regard-
ing cancer immunity and clinical responses. It is gradually 
being appreciated that normal immune regulatory mecha-
nisms are holding back an already primed immune response 
from selectively killing cancer cells in most, if not all cases, 
where clinical cancer is present. With an appreciation that 
immuno-modulation of pre-existing endogenous immune 
responses appears to occur with most cancer therapies, there 
is the serious prospect that serial immune monitoring might 
define optimal time-points for targeted administration of thera-
pies to engineer effective complete clinical responses in a much 
more predictable, reliable and durable manner in the future1. 
Effective treatments may indeed hinge on deep evolutionary 
immune and cellular mechanisms which likely underpin suc-
cessful clinical responses. If achievable, increased long-term 
survival from advanced cancer, with reduced toxicity, might 
become a reality by harnessing the immuno-modulatory capacity 
of many currently existing therapeutic agents. The cost savings 
would likely prove truly enormous144.
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from the John Radcliffe Hospital. I agree that the article contains some er  interesting ideas and 
concepts, hich ill be er  stim lator  to a ide readership, partic larl  those st d ing cancer 
and practicing cancer (oncologists) ho are slo l  becoming a are that the imm ne s stem is 
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spec lati e lect re in its c rrent format. 
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into, altho gh a paper here he is the senior a thor is listed, I do not think that it is appropriate 
therefore to refer to it in the te t as Kla mann e  al.
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This article contains some er  interesting ideas and concepts. Ho e er, to this re ie er (and ith 
the greatest respect to the a thors), it tends to read perhaps as stream of conscio sness  riting 
rather than a considered scientific article. The a thors sho  ab ndant enth siasm in their riting, 
b t this often appears to mask real scientific rigo r. It is er  diffic lt to identif  a ke  h pothesis 
(or h potheses), the str ct re of the sections seems to lack definition or foc s, and it is sometimes 
almost impossible to nderstand hat the main concl sions are from each. F rthermore, in a 
n mber of places, there seems to be a significant lack of scientific acc rac . For e ample, 
regarding some statements regarding the imm ne s stem, the a thors do not clearl  discriminate 
bet een somatic recombination ( hich applies to both T cell receptors and B cell receptors), 
somatic h perm tation ( hich applies onl  to the latter), h per ariable regions ( hich are present 
in both) and m tation (per se). As another e ample, in their disc ssion of ata ism theor , the 
a thors se the term t mo r imm nos ppression  b t appear to appl  this to the t mo r rather 
than the host, here it reall  belongs. E en the a thors  brief re ie  of the e ol tion of the 
imm ne s stem seems to lack s fficient foc s going from species to species d ring e ol tionar  
time. There are also some rather e ing thro a a  statements . As j st one e ample, regarding 
cancer, the a thors state The reason h  cancer occ rs at all in h mans and animals th s 
remains a m ster . While it is certainl  tr e that m ch remains nkno n, the a thors might 
sef ll  consider f rther B rnet s concept of t mo r s r eillance, partic larl  in its more recent 
form comprising imm noediting, eq ilibri m and escape phases. It might also be al able to 
reconsider, in relation to the imm ne s stem s apparent capacit  to eliminate t mo rs hether or 
not the imm ne s stem act all  helps to eliminate the infectio s agents (e.g. ir ses) that can 
ca se t morigenesis rather than act al or potentiall  malignant cells (and, on that point, it is 
perhaps a little s rprising that there is no mention of generic DAMPs  and PAMPs ). A f rther 
criticism is that the choice of imm nological mechanisms nder disc ssion sometimes feels rather 
random  h , for e ample, do the a thors specificall  foc s on Fc receptors rather than 
complement receptors, or C-reacti e protein rather than the man  other molec les that pla  
similar or related roles? Finall , regarding the single diagram that is presented, it is completel  
nclear h  the a thors ha e chosen to ill strate an IL-2 [sic] feedback loop ; itho t an  
j stification this seems to be o er-simplistic in the e treme. Ne ertheless, to ret rn to the initial 
point: this article does appear to contain some er  interesting material that o ld potentiall  be 
of al e to readers of the jo rnal. To do these the greatest j stice, ho e er, reall  does seem to 
req ire a er  caref l, foc ssed, and considered re riting of the present te t into a completel  
re ised and possibl  restr ct red article. 
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